skip to main content
OSTI.GOV title logo U.S. Department of Energy
Office of Scientific and Technical Information

Title: INDICATIONS, DOSAGES, AND EFFECTS OF THERAPY WITH INTERNAL USE OF RADIOIODINE, RADIOGOLD, AND RADIOPHOSPHORUS (in German)

Journal Article · · Radiobiol. Radiotherap.
OSTI ID:4133328

Therapeutic uses of I/sup 131/, Au/sup 198/, and P/sup 32/ are discussed with emphasis on optimal dose evaluation. For thyroid ablation with I/ sup 131/ in angina pectoris or cardiac insufficiency the individual dosage should be singly determined to avoid induction of myxedema. For a single treatment the dose may range between 30000 and 40000 rep and for single, fractionated doses: the range is usually between 10000 and 20000 rep. Positive results are obtained in over half the cases. Dosages for euthyroid goiter are 15000 to 20000 rep given singly each 10 weeks until clinical remission is observed, but treatment of malignant thyroid growths varies with their iodine retention capability and dosages range from 50 to 200 mC. Side effects from I/sup 131/ treatment are relatively infrequent if dosage is controlled relative to clinical status. Intravenous Au/sup 198/ therapy is used for micronodular liver and spleen tumors, lymphosarcomata, and leukemia at dosages up to 60 mC. Intrapleural Au/sup 198/ therapy is carried out with 50 to 150 mC and intraperitoneal treatment with up to 225 mC. For intratamoral treatment of the genitourinary tract up to 170 mC or 2 mC/g tumor tissue is used. Up to 50% favorable response is obtained with this and with intracavitary treatment. Radiophosphorus is used for treatment of leukemia in dosages of 1 to 5 mC/week, and for treatment of polycythemia vera at a rate near 100 mu C/g body weight. Repetition of the dosage depends on evaluation of subsequent clinical status. Frequency of leukemia in 172 P/sup 32/- treated polycythemic patients has been reported as 3%, but this frequency was 17% in 163 patients treated by other means. (BBB)

Research Organization:
Universitat, Freiburg i.B.
NSA Number:
NSA-18-005197
OSTI ID:
4133328
Journal Information:
Radiobiol. Radiotherap., Vol. Vol: 3; Other Information: Orig. Receipt Date: 31-DEC-64
Country of Publication:
Country unknown/Code not available
Language:
German

Similar Records

ON THE THERAPY OF MALIGNANT THYROID TUMORS
Journal Article · Fri May 10 00:00:00 EDT 1963 · Aerztliche Forschung (West Germany) Discontinued · OSTI ID:4133328

ATTEMPT TO DETERMINE THE OPTIMAL DOSE IN THE RADIOTHERAPY OF HYPERTHYROID DISORDERS WITH I$sup 131$ CLINICAL RESULTS IN TREATED CASES
Journal Article · Sat Feb 24 00:00:00 EST 1962 · Schweiz. Med. Wochschr. · OSTI ID:4133328

HARMFUL EFFECTS DUE TO THERAPEUTIC EMPLOYMENT OF RADIOISOTOPES
Journal Article · Fri Jan 01 00:00:00 EST 1960 · Rass. Intern. Elettron. Nucl., 7 · OSTI ID:4133328